Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Botulinum neurotoxin serotype A (BoNT/A) is widely used in therapeutics and cosmetics. The effects of multi-dosed BoNT/A treatment are well documented on the peripheral nervous system (PNS), but much less is known on the central nervous system (CNS). Here, the mechanism of multi-dosed BoNT/A leading to CNS neurodegeneration is explored by using the 3D human neuron-glia model. BoNT/A treatment reduces acetylcholine, triggers astrocytic transforming growth factor beta, and upregulates C1q, C3, and C5 expression, inducing microglial proinflammation. The disintegration of the neuronal microtubules is escorted by microglial nitric oxide, interleukin 1β, tumor necrosis factor α, and interleukin 8. The microglial proinflammation eventually causes synaptic impairment, phosphorylated tau (pTau) aggregation, and the loss of the BoNT/A-treated neurons. Taking a more holistic approach, the model will allow to assess therapeutics for the CNS neurodegeneration under the prolonged use of BoNT/A.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11022717 | PMC |
| http://dx.doi.org/10.1002/advs.202305326 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial.
Brain Behav
September 2025
Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Background And Purpose: Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.
Methods: This is an open-label, nonrandomized controlled trial.
Response to salivary gland botulinum toxin injection does not predict success from surgery for sialorrhoea (drooling) in children with neurodisability.
Eur J Pediatr
September 2025
Department of Paediatric Otolaryngology, Royal Hospital for Children, 1345 Govan Road, Glasgow, G51 4TF, UK.
Unlabelled: Drooling is a common problem in children with neurodisability, and refractory cases may require surgery. Our aim was to assess whether a child's response to salivary botulinum toxin injections would predict success or failure from subsequent surgical intervention. Retrospective case note review of all children undergoing drooling surgery between 1st January 2007 and 31st December 2023 at the Royal Hospital for Children, Glasgow.
View Article and Find Full Text PDFPerineural botulinum toxin in the management of post-traumatic headache: a case report.
Rev Esp Anestesiol Reanim (Engl Ed)
September 2025
Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.
Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).
View Article and Find Full Text PDFGut mucin fucosylation dictates the entry of botulinum toxin complexes.
bioRxiv
August 2025
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa 920-8640, Japan.
Botulinum toxins (BoNTs) are the most potent known bacterial toxins. The BoNT complex from B-Okra (large progenitor toxin complex (L-PTC)/B, hyper-oral-toxic) exerts at least 80-fold higher oral toxicity in mice compared with that from serotype A1 (L-PTC/A, non-hyper-oral-toxic). Here, we showed that L-PTC/B was predominantly absorbed through enterocytes, whereas L-PTC/A targeted intestinal microfold cells.
View Article and Find Full Text PDF"Targeting the Glabellar Frown Lines with OnabotulinumtoxinA: In-Silico Evidence Supporting Concentrated, Low-Volume Injection Protocols".
Toxicon
September 2025
Research and Innovation Hub, Innovation Aesthetics, London UK.
Botulinum Neurotoxin Type A (BoNT-A) remains the cornerstone of glabellar frown line treatment, yet conventional low-dose, high-volume protocols often result in limited durability and imprecise diffusion. This study presents multiscale, in silico framework specifically designed to evaluate high-dose (60-80 Units), low-volume (≤0.045 mL/site) BoNT-A glabellar injection strategies across anatomically realistic conditions.
View Article and Find Full Text PDF